Gilead buys out rights to cancer therapy from Jounce for $67 million By Reuters

Gilead Sciences (NASDAQ: ) will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (NASDAQ: ) for $67 million, the drugmaker said on Tuesday. The amended licensing deal will bolster Jounce's cash resources in a challenging market for biotech…#jounce #jouncetherapeutics #gs1811 #gilead
Source: Reuters: Health - Category: Consumer Health News Source Type: news